Ranbaxy Laboratories Ltd, India's biggest drugmaker, considers acquisitions aimed at expanding operations in the US, south and central America and its home market to be priorities.
Ranbaxy made eight acquisitions last year, buying South African company Be-Tabs Pharmaceuticals and Romania's Terapia. The US $3.4 billion company has been built over the past three decades by copying blockbuster drugs such as Bayer AG's Cipro and selling them for a fraction of the price in countries including France, Germany and the US.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment